Go to content
Galapagos NV

Galapagos NV

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 17 mrt 2015 - 07:35
Statutaire naam Galapagos NV
Titel Galapagos regains rights to GLPG1690, announces end of alliance with Janssen
Bericht Fully owned and proprietary clinical asset for pulmonary fibrosis GLPG1690 acts on autotaxin target Novel mode of action, originating from Galapagos target discovery engine Filing for Phase 2 clinical trial in 2015 Mechelen, Belgium; 17 March 2015 - Galapagos NV (Euronext: GLPG) announced that Janssen Pharmaceutica NV and Galapagos have mutually agreed to terminate the inflammation alliance and option agreements between the companies. Galapagos views the molecules emerging from the alliance as strong additions to its growing proprietary pipeline. Among others, all rights to candidate drug GLPG1690, a selective autotaxin inhibitor, return to Galapagos. Galapagos has successfully completed a First-in-Human Phase 1 trial for GLPG1690 and is preparing a Phase 2 clinical trial in idiopathic pulmonary fibrosis (IPF).